JP2022525208A5 - - Google Patents

Info

Publication number
JP2022525208A5
JP2022525208A5 JP2021555491A JP2021555491A JP2022525208A5 JP 2022525208 A5 JP2022525208 A5 JP 2022525208A5 JP 2021555491 A JP2021555491 A JP 2021555491A JP 2021555491 A JP2021555491 A JP 2021555491A JP 2022525208 A5 JP2022525208 A5 JP 2022525208A5
Authority
JP
Japan
Prior art keywords
dsrna
nucleotides
rna
compound
oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021555491A
Other languages
English (en)
Japanese (ja)
Other versions
JP7687685B2 (ja
JP2022525208A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/022748 external-priority patent/WO2020190768A1/en
Publication of JP2022525208A publication Critical patent/JP2022525208A/ja
Publication of JP2022525208A5 publication Critical patent/JP2022525208A5/ja
Priority to JP2025081846A priority Critical patent/JP2025156319A/ja
Application granted granted Critical
Publication of JP7687685B2 publication Critical patent/JP7687685B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021555491A 2019-03-15 2020-03-13 組織特異的なａｐｏｅ調節のためのオリゴヌクレオチド Active JP7687685B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025081846A JP2025156319A (ja) 2019-03-15 2025-05-15 組織特異的なａｐｏｅ調節のためのオリゴヌクレオチド

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962819189P 2019-03-15 2019-03-15
US62/819,189 2019-03-15
US201962864797P 2019-06-21 2019-06-21
US62/864,797 2019-06-21
US201962951441P 2019-12-20 2019-12-20
US62/951,441 2019-12-20
PCT/US2020/022748 WO2020190768A1 (en) 2019-03-15 2020-03-13 Oligonucleotides for tissue specific apoe modulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025081846A Division JP2025156319A (ja) 2019-03-15 2025-05-15 組織特異的なａｐｏｅ調節のためのオリゴヌクレオチド

Publications (3)

Publication Number Publication Date
JP2022525208A JP2022525208A (ja) 2022-05-11
JP2022525208A5 true JP2022525208A5 (https=) 2023-03-17
JP7687685B2 JP7687685B2 (ja) 2025-06-03

Family

ID=72520528

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021555491A Active JP7687685B2 (ja) 2019-03-15 2020-03-13 組織特異的なａｐｏｅ調節のためのオリゴヌクレオチド
JP2025081846A Pending JP2025156319A (ja) 2019-03-15 2025-05-15 組織特異的なａｐｏｅ調節のためのオリゴヌクレオチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025081846A Pending JP2025156319A (ja) 2019-03-15 2025-05-15 組織特異的なａｐｏｅ調節のためのオリゴヌクレオチド

Country Status (7)

Country Link
US (1) US20200362341A1 (https=)
EP (1) EP3937951A4 (https=)
JP (2) JP7687685B2 (https=)
CN (1) CN113811311A (https=)
AU (1) AU2020239987A1 (https=)
CA (1) CA3133241A1 (https=)
WO (1) WO2020190768A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160319278A1 (en) 2015-04-03 2016-11-03 University Of Massachusetts Fully stabilized asymmetric sirna
WO2017030973A1 (en) 2015-08-14 2017-02-23 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
JP7406793B2 (ja) 2017-06-23 2023-12-28 ユニバーシティー オブ マサチューセッツ ２テイル自己デリバリー型ｓｉＲＮＡおよび関連方法
US11279930B2 (en) 2018-08-23 2022-03-22 University Of Massachusetts O-methyl rich fully stabilized oligonucleotides
KR20220047989A (ko) 2019-08-09 2022-04-19 유니버시티 오브 매사추세츠 Snp를 표적화하는 화학적으로 변형된 올리고뉴클레오타이드
WO2021041247A1 (en) * 2019-08-23 2021-03-04 University Of Massachusetts O-methyl rich fully stabilized oligonucleotides
US12365894B2 (en) 2019-09-16 2025-07-22 University Of Massachusetts Branched lipid conjugates of siRNA for specific tissue delivery
EP4065600A1 (en) 2019-11-25 2022-10-05 Cornell University Apoe gene therapy
IL297702A (en) * 2020-04-27 2022-12-01 Alnylam Pharmaceuticals Inc Apolipoprotein e (apoe) irna agent compositions and methods of use thereof
WO2021242883A1 (en) 2020-05-26 2021-12-02 University Of Massachusetts Synthetic oligonucleotides having regions of block and cluster modifications
CN114716518A (zh) * 2021-01-06 2022-07-08 圣诺制药公司 一种能够抑制pcsk9表达的分子构造及药物组合物
US20240175028A1 (en) * 2021-03-05 2024-05-30 Alnylam Pharmaceuticals, Inc DOSING OF siRNA COMPOUNDS TO THE CISTERNA MAGNA
WO2022204430A1 (en) * 2021-03-24 2022-09-29 Atalanta Therapeutics, Inc. Double-stranded sirna having patterned chemical modifications
WO2022271666A1 (en) * 2021-06-22 2022-12-29 University Of Massachusetts OLIGONUCLEOTIDES FOR IFN-γ SIGNALING PATHWAY MODULATION
US20250011404A1 (en) * 2021-11-09 2025-01-09 Children's National Medical Center Targeting apoe enhances t-cell killing in cancer immunotherapy
JP2025532984A (ja) * 2022-09-30 2025-10-03 ユニバーシティー オブ マサチューセッツ オリゴヌクレオチドの眼送達
WO2024233864A2 (en) * 2023-05-10 2024-11-14 Dicerna Pharmaceuticals, Inc. Galnac-conjugated rnai oligonucleotides
WO2025213111A2 (en) * 2024-04-05 2025-10-09 Cornell University Aav expression of mirna to suppress human apoe mrna
WO2025240846A1 (en) * 2024-05-17 2025-11-20 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating apoe expression
CN118460654B (zh) * 2024-07-10 2025-02-14 凯莱英医药集团（天津）股份有限公司 一种Givosiran的制备方法
WO2026057066A1 (zh) * 2024-09-14 2026-03-19 瑞典瑞博科尔制药公司 寡核苷酸、寡核苷酸缀合物及组合物和用途
WO2026067590A1 (zh) * 2024-09-27 2026-04-02 南京金斯瑞生物科技有限公司 修饰的双链rna分子

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003295600A1 (en) * 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
US20060257851A1 (en) * 2002-11-26 2006-11-16 Itzhak Bentwich Bioinformatically detectable group of novel viral regulatory genes and uses thereof
EP1989307B1 (en) * 2006-02-08 2012-08-08 Quark Pharmaceuticals, Inc. NOVEL TANDEM siRNAS
US20070248599A1 (en) * 2006-02-21 2007-10-25 Jordan Tang Treatment of alzheimer's disease with inhibitors of apoe binding to apoe receptor
US8178503B2 (en) * 2006-03-03 2012-05-15 International Business Machines Corporation Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes
WO2008021353A2 (en) * 2006-08-14 2008-02-21 Guangxiang Luo Composition and method for controlling hepatitis c virus infection
WO2009147684A2 (en) * 2008-06-06 2009-12-10 Quark Pharmaceuticals, Inc. Compositions and methods for treatment of ear disorders
CN103223177B (zh) * 2009-05-06 2016-08-10 库尔纳公司 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
EP2470656B1 (en) * 2009-08-27 2015-05-06 Idera Pharmaceuticals, Inc. Composition for inhibiting gene expression and uses thereof
KR101029699B1 (ko) * 2010-09-29 2011-04-18 동국대학교 산학협력단 생약추출물을 유효성분으로 함유하는 알쯔하이머 치매 치료 및 예방용 조성물
US20150141320A1 (en) * 2012-05-16 2015-05-21 Rana Therapeutics, Inc. Compositions and methods for modulating gene expression
WO2013173652A1 (en) * 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating gene expression
WO2013181618A2 (en) * 2012-05-31 2013-12-05 The Trustees Of Columbia University In The City Of New York Methods to treat alzheimer's disease using apoe inhibitors
EP3191578B1 (en) * 2014-09-12 2020-11-04 Whitehead Institute for Biomedical Research Cells expressing apolipoprotein e and uses thereof
WO2016064895A1 (en) * 2014-10-20 2016-04-28 The Brigham And Women's Hospital, Inc. Targeting apolipoprotein e (apoe) in neurologic disease
KR20160121450A (ko) * 2015-04-10 2016-10-19 경북대학교병원 콜레스테롤 축적에 의한 질환 진단용 마커 조성물 및 이의 이용
US10478503B2 (en) * 2016-01-31 2019-11-19 University Of Massachusetts Branched oligonucleotides
JP6944942B2 (ja) * 2016-02-02 2021-10-06 オリックス ファーマシューティカルズ，インコーポレーテッド ＩＬ４Ｒα、ＴＲＰＡ１、またはＦ２ＲＬ１を標的とするＲＮＡ複合体を用いたアトピー性皮膚炎および喘息の治療
EP4081302A4 (en) * 2019-12-23 2025-01-29 University Of Massachusetts OLIGONUCLEOTIDES FOR TISSUE-SPECIFIC GENE EXPRESSION MODULATION

Similar Documents

Publication Publication Date Title
JP2022525208A5 (https=)
JP2022528487A5 (https=)
US20230020192A1 (en) Compounds and methods for modulating c90rf72
JP2018516091A5 (https=)
US10538763B2 (en) Compounds and methods for modulation of DUX4
JP2021533762A5 (https=)
JP2022526419A (ja) 中枢神経系における遺伝子発現を阻害するための組成物及び方法
JP2021533804A5 (https=)
WO2018062510A1 (ja) オーバーハングを有する二本鎖核酸複合体
WO2023022229A1 (ja) モルホリノ核酸を含む修飾ヘテロ核酸
US20250270562A1 (en) Bis-rnai compounds for cns delivery
KR20220069103A (ko) 최소 플루오린 함량을 갖는 작은 간섭 rna의 화학적 변형
JP2023518268A5 (https=)
EP2062586B1 (en) Use of low doses of oligonucleotides antisense to tgf-beta1 genes in the treatment of tumors
CN115397436A (zh) 用于抑制PNPLA3表达的RNAi剂、其药物组合物和使用方法
JP2023538283A (ja) 代謝症候群の治療のための組成物及び方法
JP7560616B2 (ja) 膜貫通型セリンプロテアーゼ６（ｔｍｐｒｓｓ６）発現を阻害するための組成物および方法
JP2020531450A (ja) 調整性ｒｅｖｅｒｓｉｒ（商標）化合物
JP2019527549A (ja) 転写プロセシングの調節のための化合物及び方法
WO2021070959A1 (ja) 修飾ヘテロ核酸
WO2021157730A1 (ja) 核酸医薬とその使用
WO2024164008A1 (en) Products and compositions
JP2025542580A (ja) 遺伝子サイレンシング技術としての、デオキシリボヌクレオチドが散在している短鎖二重鎖ｒｎａ、およびその使用
JP6934695B2 (ja) 核酸医薬とその使用
AU2023267664A1 (en) Compositions and methods for inhibiting snca expression